

Targeting RNA Modifications for Drug Development: The Role of Epitranscriptomics in Pharmacology

Nafiu, Sani Barau, Tsutsu, Terva Collins, Aliyu Muqaddas Abdulkadir

Federal University Wukari, Taraba State, Nigeria

nafiu@fuwukari.edu.ng

Article Info:

Submitted:	Revised:	Accepted:	Published:
Feb 6, 2026	Mar 6, 2026	Mar 18, 2026	Mar 23, 2026

Abstract

Epitranscriptomics has emerged as an additional regulatory layer of gene expression mediated by chemical modifications on RNA molecules, with important implications for cellular function and disease. This review synthesizes recent advances in epitranscriptomic research, focusing on major RNA modifications, including N⁶-methyladenosine, pseudouridine, and 5-methylcytosine, and their mechanistic roles in regulating RNA stability, splicing, localization, and translational efficiency through the coordinated actions of writers, erasers, and readers. It further examines the dynamic regulation of RNA modifications under pathological stress conditions and highlights their contribution to disease pathogenesis, particularly in cancer, metabolic disorders, and neurological diseases. In addition, the review discusses emerging pharmacological strategies targeting epitranscriptomic regulators, including small-molecule inhibitors and RNA-based therapeutic approaches. The evidence collectively indicates that RNA modifications represent promising therapeutic targets, while also underscoring persistent challenges related to target specificity, delivery efficiency, and off-target effects. The review concludes that epitranscriptomics constitutes a rapidly evolving frontier in drug discovery and precision pharmacology by expanding

current understanding of disease mechanisms and offering new directions for therapeutic innovation.

Keywords: Epitranscriptomics; RNA Modifications; N⁶-Methyladenosine; Drug Discovery; Precision Pharmacology

Introduction

The discovery of pseudouridine in 1957 was a key development in molecular biology, exposing RNA's propensity for chemical modifications (Arzumanian *et al.*, 2022). These modifications occur at the post-transcriptional stage of gene expression on numerous RNA molecules, including transfer RNA (tRNA), messenger RNA (mRNA), long non-coding RNA (lncRNA), and ribosomal RNA (rRNA) (Shi *et al.*, 2020). These modifications influence the stability, location, splicing, degradation, and translational efficiency of RNA, although they do not modify the nucleotide sequence itself.

Currently, over 170 post-transcriptional modifications have been discovered in RNA, occurring in organisms ranging from archaea and bacteria to eukaryotes (Qui *et al.*, 2023; Nossent *et al.*, 2023). Some of these modifications include N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), pseudouridine (Ψ), and N¹-methyladenosine (m¹A). The most abundant and well-characterized internal modification in eukaryotic mRNAs is N⁶-methyladenosine (m⁶A) (Qui *et al.*, 2023).

These alterations are deposited onto and erased from RNA molecules by the operations of writer (e.g., METTL3, METTL14, NSUN (NSUN1-7 and WTAP) and eraser enzymes (e.g., FTO, ALKBH5, ALKBH1, and ALKBH3). These modifications are recognized and interpreted by reader proteins, such as YTHDF1-3, YTHDC1-2, IGF2BP1-3, HNRNPA2B1, and eIF3 (Wilkinson *et al.*, 2022). These enzymes ultimately determine the RNA fate and gene expression. The regulatory action of the readers ultimately controls the RNA destiny and gene expression.

The chemical diversity and regulatory integrity of RNA molecules are, to a significant extent, mediated by a range of covalent chemical modifications of the RNA nucleotides, collectively known as the epitranscriptome. When examining the significance of RNA modifications within the broader landscape of epigenetic control, it is necessary to contrast them with DNA and histone changes, two well-known established mechanisms in

the field of epigenetics. A narrow repertoire of epigenetic alterations in DNA is observed compared to epitranscriptomic modifications. DNA methylation is the best-characterized epigenetic process. It frequently occurs on cytosines (5mC, 5hmC, 5fC, and 5caC) and is the most abundant and lasting epigenetic mark in eukaryotes that is strongly related to gene regulation (Esteve-Puig *et al.*, 2020). Histones, on the other hand, are subject to many post-translational alterations, including acetylation, methylation, and ubiquitination, influencing chromatin structure, and function, consequently regulating access to genetic information (Xu *et al.*, 2022). Histone PTMs are introduced and erased by diverse kinds of enzymes (writers and erasers, respectively), which typically reside in huge protein complexes having various enzymatic activities (Jurkowska, 2024). While both DNA and histone modifications influence gene expression at the transcriptional level, RNA modifications function post-transcriptionally, affecting how and when mRNAs are translated into proteins.

Furthermore, RNA modifications are crucial in cellular functions, regulating mRNA stability and translation, while others may target mRNA for degradation and inhibit its translation (Qui *et al.*, 2023). They play a role in various human diseases, including cancer, neurological disorders, cardiovascular diseases, metabolic disorders, and developmental and genetic abnormalities. The epitranscriptome, with its fast and reversible effects, is excellent for precision-targeted treatments. The growing understanding of RNA modification and its involvement in biological processes has offered new promise in the diagnosis, treatment, and prevention of a range of disorders, making it an interesting target for therapeutic intervention.

Common RNA Modifications

Out of the >170 post-transcriptional RNA modifications documented to date, a (sub)set, including N6-methyladenosine (m⁶A), pseudouridine (Ψ), 5-methylcytosine (m⁵C), and N1-methyladenosine (m¹A), has been discovered as particularly abundant and functionally relevant. Collectively, these alterations operate as molecular switches and checkpoints that program gene expression events with temporal and spatial accuracy.

N6-Methyladenosine (m6A)

N6-Methyladenosine (m⁶A) is one of the most abundant posttranscriptional modifications on RNA's in eukaryotes, effecting various RNA metabolic processes, including RNA alternative splicing, translation efficiency, degradation (Huang *et al.*, 2020). According to Qui *et al.*, (2023) m6A altered site notably localizes at the beginning of the 3'

untranslated region (UTR) at the stop codon, often conserved within the consensus pattern 5'-RRACH-3' (R represents G, A, or U; H stands for U, A, or C). Its deposition is mediated by a multicomponent methyltransferase complex, the adenosines are methylated by m⁶A-methyltransferases, referred to as m⁶A 'writers', which are part of the so-called 'm⁶A writer complex', consisting of methyltransferases METTL3 and METTL14 together with their cofactor Wilms' tumor 1-associating protein (WTAP) (Nossent *et al.*, 2023). Since it is a reversible process, it can be removed by demethylases, which have been found to include FTO and alkylated DNA repair protein AlkB homolog 5 (ALKBH5). Regulation also involves m⁶A-binding proteins, such as YTH domain family 1–3 (YTHDF1–3), YTHDC1, and YTHDC2, which exert regulatory effects by selective recognition. For instance, m⁶A residues can alter the stability of target transcripts by engaging with YTHDF2 or increase protein synthesis by connecting with YTHDF1 (Liang *et al.*, 2024).

The emergence of m⁶A sequencing (m⁶A-seq) technologies and the identification of m⁶A modification writers, erasers, and readers have prepared the ground for inquiry into the function of m⁶A mRNA modification in varied disorders (Arzumanian *et al.*, 2022). Recent findings also tie m⁶A to oncogenic signaling, indicating its dual activity as both a tumor suppressor and promoter, depending on cellular context (Sun *et al.*, 2023; Cui *et al.*, 2022).




Figure 1: The structure and reversibility of m⁶A modifications and the function of m⁶A through recognition by the reader protein (Liu *et al.*, 2023).

Pseudouridine (Ψ)

Pseudouridine (Ψ) was the first modified ribonucleoside identified in 1951 and is the most abundant post-transcriptionally modified nucleotide in RNA from all three domains of life. It is discovered in a wide spectrum of RNA, from tRNA and rRNA to distinct snRNAs (Arzumanian *et al.*, 2022). Pseudouridine (Ψ), a C–C glycosyl isomer arises via Pseudouridylation (isomerization of uridine), mediated by pseudouridine synthases (PUS) which include TruA family (PUS1, PUSL1, PUS3), TruB family (TRUB1, TRUB2), TruD family (PUS7, PUS7L), RluA family (RPUSD1, RPUSD2, RPUSD3, RPUSD4), and PUS10 in human cells (Zhao *et al.*, 2025). Pseudouridylation refers to the process in which the pyrimidine ring of uridine (U) rotates 180° with C 3 and C6 as an axis to form pseudouridine (Ψ), which is the most abundant modified nucleoside in human cells (Barbieri *et al.*, 2020). Isomerization of uridine to pseudouridine requires cleavage of the glycosidic bond between N1 and C1', rotation of the base, and subsequent reattachment of the base to the ribose via C5, resulting in enhanced stabilization of RNA conformations, destabilization, base stalking, altered hydrogen bonding properties and interactions with varied RNA binding proteins (Borchardt *et al.*, 2020). Recent research has revealed Ψ modifications in various RNA types, including messenger RNA (mRNA), transfer RNA (tRNA, tsRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), and long noncoding RNA (lncRNA). Inducible pseudouridylation of mRNA occurs under stress, viral infection, or cellular transformation. This modification, defined by a geometrically equivalent Watson–Crick base, enhances the thermodynamic stability of RNA compared with the normal uridine (U)-adenine (A) base pair, and also plays roles in ribosome assembly (Liu *et al.* 2024). Ψ provides crucial tasks in ribosome construction, tRNA function, pre-mRNA splicing, and translation fidelity. Moreover, pseudouridylated nucleotides are increasingly significant in mRNA-based therapeutics, notably in vaccines, as they minimize immunogenicity and enhance translational efficiency (Zhao *et al.*, 2025)




Figure 2: Schematic presentation of the Pseudouridation reaction: It results in an extra hydrogen bond donor (d) and the same number of hydrogen bond acceptors (a) (Zhao *et al.*, 2018).

5-Methylcytosine (m⁵C)

5-Methylcytosine (m⁵C) is a well-characterized mark in DNA that is crucial in gene expression and epigenetic regulation (Shi *et al.*, 2020). However, it also exists abundantly in RNA, tRNA, rRNA, mRNA, and ncRNA., where it affects RNA structure, stability, transport, and translation into proteins (Xue *et al.*, 2022). m⁵C is dynamically regulated by “writers,” “erasers”, and “readers”. m⁵C is implanted via a sequence of m5C methyltransferases (“writers”), such as NOP2, NSUN2, NSUN3, NSUN4, NSUN5, NSUN6, NSUN7, DNMT1, TRDMT1, DNMT3A, and DNMT3B (Gu *et al.*, 2021). The elimination process is catalyzed by TETs. The Aly/REF nuclear export factor (ALYREF) might detect and bind to m⁵C sites for biological function (Zhang *et al.*, 2021). m⁵C is localized in 5'UTRs and coding regions of mRNAs, where it may increase ribosome loading or shield mRNA from endonuclease cleavage (Cheng *et al.*, 2021). Dysregulation of m⁵C has been linked in stem cell differentiation, neurological disorders, and tumor metastasis, principally via its impact on non-coding RNAs and cancer-related genes (Han *et al.*, 2023; Xue *et al.*, 2022). Recent sequencing developments (e.g., bisulfite sequencing for RNA) have mapped m⁵C patterns with single-nucleotide resolution, showing its universal functional relevance (Han *et al.*, 2023).




Figure 3: The structure and reversibility of m^5C modifications through the recognition by reader proteins (Song *et al.*, 2022).

N 1-Methyladenosine (m^1A)

N1-methyladenosine (m^1A) is an adenosine molecule whose N1-position is methylated. m^1A methylation is a pervasive, prolific, and conserved internal post-transcriptional alteration throughout bacterial and eukaryotic RNAs, notably in higher eukaryotic cells (Xiong *et al.*, 2022). It is common in several kinds of RNA, including rRNA, tRNA, mRNA, mtRNA, ncRNA, and enhancer RNA (eRNA) (Wang *et al.*, 2024). These modifications participate in translation, interpretation of codons, preservation of stability, export and translation in the different types of RNAs (Huang *et al.*, 2019; Xiong *et al.*, 2022). It is catalyzed by enzymes such as TRMT6/61A. m^1A impacts Watson-Crick base pairing, influencing RNA secondary structure and translation. In contrast to m^6A , m^1A often localizes to the 5' untranslated regions and start codons, where it promotes translation initiation under specific physiological conditions. It is dynamically regulated by ALKBH1, a known m^1A demethylase. The biological relevance of m^1A includes functions in metabolic management, hypoxic stress response, and stem cell pluripotency, and its dysregulation has been identified in several malignancies (Sweef *et al.*, 2024; Wang *et al.*, 2024).




Figure 4: List the identified regulators of m¹A modification (Wang *et al.*, 2024).

Mechanistic Links between RNA Modifications and Gene Expression

RNA modifications serve as critical posttranscriptional regulators of gene expression programs and their correct deposition is essential for normal development (Artika *et al.*, 2025). Accumulating evidence reveals that the dynamics of internal RNA modifications play critical roles in multiple RNA-processing events including splicing, transport, translation, and degradation all of which in turn regulate gene expression. The expression patterns of RNA modifications and also of their regulators have the potential to be used as biomarkers for diseases or absorption of disease-causing hazard, acting as molecular switches that determine the fate and function of specific transcripts (Chen *et al.*, 2023).

The role of m⁶A in the mRNA's life cycle is complex, involving the reader, writer, and eraser. The m⁶A modification is installed co-transcriptionally by a methyltransferase complex (MTC), which includes the METTL3 catalytic component and other accessory subunits and other accessory subunits such as METTL14 and WTAP (Cheng *et al.*, 2024). Demethylases remove this complex, and RNA-binding proteins interpret it. The writer complex binds to mRNAs and transfers the methyl group to specific adenosines, usually containing RRACH motifs. METTL3 has been implicated in various biological processes, including modulation of alternative splicing, stabilization of target mRNAs, regulation of hematopoietic stem cell self-renewal, and involvement in tumorigenesis. m⁶A erasers, also known as demethylases, shape the m⁶A epitranscriptome by converting m⁶A into adenosine

(Chen *et al.*, 2024). The contribution of m⁶A modifications to mRNA metabolism and cell fate transition is mediated by m⁶A readers, which bind to m⁶A-modified RNAs and recruit interacting proteins to regulate RNA metabolism (Zhang *et al.*, 2023).

Moreover, RNA modifications often occur at key regulatory regions, such as 5' UTRs, stop codons, and splice junctions, further enhancing their influence over transcript isoform diversity and translation efficiency (Höfler and Duss, 2023). As such, RNA modifications have emerged as central modulators of cellular identity and function, playing critical roles in processes ranging from stem cell pluripotency to immune cell activation and tissue repair.

RNA Modification as a Dynamic Regulator under Pathological Stress

One of the most intriguing aspects of RNA modifications is their dynamic behavior under stress conditions. Environmental and pathological stresses including oxidative damage, inflammation, hypoxia, and viral infection trigger widespread changes in the RNA epitranscriptome. These changes help the cell quickly recalibrate its gene expression profile to survive, adapt, or initiate programmed cell death when necessary.

Both m⁶A and m⁵C pathways play important roles in regulating the cellular response to oxidative stress, a condition caused by disrupted redox homeostasis, including the generation of reactive oxygen species (ROS) promoting their efficient translation to support cellular repair mechanisms and antioxidant responses. Thalhammer and colleagues identified that the *ALKBH5* promoter was up-regulated in response to hypoxia across several different cancer cell lines (Wilkinson *et al.*, 2021).

In pathological contexts like neurodegeneration, cancer, and chronic inflammation, stress-induced changes in RNA modifications can become maladaptive. A recent study on Alzheimer's disease (AD) revealed that, postmortem human brains exhibit cell type-specific m⁶A dysregulation, with pyramidal neurons containing lower m⁶A and METTL3 levels associated with memory deficits, neuronal death, and neurite degeneration (Zhao *et al.*, 2021). Similarly, in degenerative conditions like intervertebral disc disease, dysregulated m⁶A profiles correlate with extracellular matrix remodeling, inflammatory gene activation, and progression of tissue degeneration (Liu *et al.*, 2025).

Importantly, stress-induced RNA modifications are reversible, providing therapeutic opportunities. Modulating these marks using small molecules could restore balanced gene expression under pathological stress and prevent irreversible cellular damage.

Dysregulation of RNA Modifications in Human Disease

The discovery of dynamic and reversible RNA modifications has introduced a new dimension to gene control and cellular homeostasis. Among these, N6-methyladenosine (m⁶A), together with other marks like as m⁵C, pseudouridine (Ψ), and m¹A, operates as a post-transcriptional epigenetic layer that influences RNA splicing, stability, translation, and degradation. Dysregulation of RNA-modifying enzymes known as writers, erasers, and readers has been progressively implicated in the pathophysiology of a wide range of human disorders. These include malignancies, neurological diseases, metabolic abnormalities, and immunological dysregulation. The context-dependent activity of RNA modifications has not only revealed novel disease pathways but has also suggested therapeutic possibilities for targeting RNA methylation systems. The context-dependent activity of RNA modifications has not only revealed novel disease mechanisms but has also opened therapeutic avenues for targeting RNA methylation systems.

Cancer: Aberrant m⁶A Regulation in Tumor Progression

Deviant RNA modifications disrupt gene expression by modifying the stability and translational efficiency of mRNAs that encode proteins critical for DNA repair, cell cycle regulation, and apoptosis, potentially resulting in heightened mutation rates and genomic instability (Yang *et al.*, 2022; Bai *et al.*, 2023). Wang *et al.* (2015) established that m⁶A influences mRNA translation efficiency, whereas Mendel *et al.* (2021) revealed that m⁶A at splice sites obstructs U2AF35 binding, hence inhibiting RNA splicing.

The most critical RNA modifications implicated in tumorigenesis include, 5-methylcytosine (m⁵C), N1-methyladenosine (m¹A), N6-methyladenosine (m⁶A), pseudouridine (Ψ), and others like 7-methylguanosine (m⁷G) and adenosine-to-inosine (A-to-I) editing (Chen *et al.*, 2024). These modifications alter the chemical structure of RNAs, directly affecting gene expression and various biological processes. Of all this modifications m⁶A has gained more attention due to it's the following: (1) it is the most abundant internal

mRNA modification in eukaryotes, affecting thousands of transcripts, (2) it is extensively mapped using techniques like MeRIP-seq, making it easier to study, (3) It is dynamics and reversible thus enabling multiple intervention points, (4) plays pivotal roles in cancer hallmarks; cell proliferation, apoptosis, angiogenesis, metastasis, immune evasion, and drug resistance and a lot more there is.

Dysregulated m⁶A writers exhibit oncogenic functions: METTL3 augments the translation of critical oncogenic mRNAs such as c-MYC, BCL2, PTEN, and MDM2, while METTL14 upregulated in AML increases m⁶A modification on MYB and MYC transcripts, hence facilitating cell survival and proliferation (Guan, 2024; Du *et al.*, 2024). Moreover, METTL3 facilitates epithelial-to-mesenchymal transition (EMT) and metastasis by augmenting the mRNA stability of ZEB1 and SNAIL through m⁶A alteration (Ouyang *et al.*, 2024; Li *et al.*, 2025).

Additionally, m⁶A erasers including FTO and ALKBH5 are also of pivotal importance. (A) FTO is frequently overexpressed in glioblastoma and AML where it removes m⁶A modifications from a subset of tumor suppressor transcripts to stabilize them aberrantly. ALKBH5 maintains breast cancer CSC properties by removing methylation from and stabilizing pluripotency-related transcripts including NANOG and SOX2 (Zhang *et al.*, 2021). Collectively, our findings highlight the bifunctional role of m⁶A regulators in cancer biology, functioning as either oncogenes or tumor suppressors based on the cellular context.

Neurological Disorders: Role of RNA Methylation in Brain Development

The central nervous system demonstrates elevated RNA methylation activity, encompassing the initial fate determination of neural stem/progenitor cells, the production of neurons and glial cells, the migration of post-mitotic immature neurons, synapse formation, programmed cell death, synaptic reorganization, and the maintenance and reconstruction of neurons during the postnatal period (Park et al., 2020). Research on axonal regeneration in adult mouse dorsal root ganglion demonstrated the significant involvement of m⁶A methylation in both normal physiology and responses to pathogenic stimuli within the adult mammalian nervous system (Wardowska, 2021). The hippocampus and cortex are the principal brain areas implicated in the pathophysiology of Alzheimer's disease (AD). Preclinical investigations have demonstrated specific functions of RNA methyltransferases and demethylases in cortical development and hippocampus

neurogenesis (Du et al., 2021). For instance, METTL3 significantly impacts the regulation of the neural progenitor pool and neuronal production, in contrast to FTO (Du et al., 2021). Its silencing leads to pronounced abnormalities in dendritic spines and synapses, accompanied by extensive neuronal death in the hippocampus—hallmarks of Alzheimer's disease (Zhao et al., 2021). The examination of human samples from individuals with Alzheimer's disease indicated a decrease in the mRNA expression levels of METTL3 and FTO relative to the control group (Li et al., 2022). In contrast, the downregulation of FTO facilitates memory reconsolidation (Chang et al., 2023), demonstrating that an accurate global m6A methylation level and a delicate equilibrium between methyltransferases and demethylases are essential for optimal brain function.

Pseudouridine and ac4C are two additional RNA markers recognized for their roles in neurodegenerative symptoms by influencing ribosomal efficiency and mitochondrial function. This information indicates an increasing awareness that epitranscriptomic dysregulation is fundamental to brain dysfunction, rather than merely a consequence of disease.

Metabolic and Immune Diseases

RNA changes have been increasingly intimately connected in recent years with immune homeostasis and metabolic signaling circuit regulation. m6A regulates genes linked to insulin sensitivity, adipocyte formation, and the metabolism of fats and carbs. According to Wang et al. (2021), m6A methylation is regarded to be critical for the immune response's operation in both healthy persons and patients with a range of disorders. T cell development and function in the thymus can be severely impacted by abnormalities in the mRNA methylome, which can result in aberrant immunological responses. In the absence of METTL3, T cell differentiation and proliferation have been reported to reduce (Chao et al., 2021). METTL3 decrease in Tregs enables the SOCS gene to become more stable, which prevents the IL-STAT5 pathway's cytokine signaling from being transduced (Lv et al., 2021). METTL3 blockade is probably a significant component in immune homeostasis regulation and the decrease of the onset of numerous autoimmune illnesses (Zhang et al., 2024). METTL3 reduction in dendritic cells inhibits the phenotypic and functional development of Dendritic cells, as seen by lower expression of CD40 and CD80, two costimulatory markers, and restricted IL2 production. In vitro and in vivo activation of T-cell responses is influenced by these METLL3-associated changes in DC activity (Yao et

al., 2021). Alike, YTHDF1 has been found to alter some immune genes translation in DCs, thereby modifying DCs interaction with T cells (Wen et al., 2024). With the rising information regarding RNA methylome and its impact on living organisms' physiological processes, the interest in exploring its function in human diseases is developing. Autoimmune illnesses, next to cancer, have risen to the forefront in the field of epitranscriptomic study. The available evidence about m6A modification may show some association between RNA methylation levels and autoimmune development and progression (Paramasivam et al., 2020). Pathogens also utilize the host's epitranscriptome. For instance, SARS-CoV-2 RNA is m6A-modified, which helps the virus elude immune detection and boosts translation efficiency (Zou et al., 2024). This dynamic interaction between host and pathogen reveals RNA methylation as a critical contact in antiviral defense.

Therapeutic Targeting of RNA Modifications

Small-Molecule Modulators of RNA-Modifying Enzymes

The therapeutic strategy of RNA modifications, particularly m⁶A methylation, is based on their reversible nature, making them an attractive target for epitranscriptomic regulation. The enzymatic machinery involved in these modifications, writers, erasers, and readers governs RNA fate and function. This reversible nature allows for the development of small-molecule inhibitors targeting RNA-modifying enzymes, promising for cancer, neurological diseases, and immunotherapy.

Inhibitors of Methyltransferases

METTL3, the catalytic subunit of the m6A methyltransferase complex, is frequently upregulated in tumors and is responsible for installing m6A marks that enhance the translation of oncogenic transcripts. Researchers are developing METTL3 inhibitors to address the increasing roles of the enzyme in various pathologies. The main target of inhibitor design is the MTD of METTL3, which is primarily aimed at competing with the cosubstrate SAM (Fiorentino et al., 2023).

The METTL (methyltransferase-like) proteins are a family of methyltransferases responsible for catalyzing the transfer of a methyl group from a donor molecule (such as S-adenosyl methionine) to specific target sites on RNA molecules (Wong and Eirin-Lopez,

2021). The vertebrate METTL family consists of 33 members, including METTL1, METTL3, METTL5, METTL6, METTL14, and METTL16, each of which possesses a conserved SAM-binding domain residing in part of the overall 7BS structure (Tooley *et al.*, 2023). Although enzymes modifying similar substrates did not share a common ancestor, they do largely group phylogenetically. The primary function of METTL proteins is to add methyl groups to specific nucleotides within substrate molecules, including proteins, nucleic acids, and other small-molecule metabolites. Fourteen of the 33 METTL family members methylate DNA or RNA (Tooley *et al.*, 2023). The most extensively studied RNA methylation target of METTL proteins is m⁶A, catalyzed by the METTL3-METTL14 m⁶A methyltransferase complex (Jiang *et al.*, 2021). Accumulating evidence has shown that METTL3 may act as a potential therapeutic target, dependent or independent of m⁶A modification.

Researchers are developing METTL3 inhibitors to address the increasing roles of the enzyme in various pathologies. The main target of inhibitor design is the MTD of METTL3, which is primarily aimed at competing with the co-substrate SAM (Fiorentino *et al.*, 2023). Most small-molecule inhibitors targeting the METTL family have been developed against METTL3.

Demethylase Inhibitors

FTO and ALKBH5 are m⁶A demethylases that remove methyl groups from RNA, thus reversing methylation-induced regulatory effects. Overexpression of FTO in various cancers correlates with chemoresistance, stemness, and poor prognosis. Therefore, pharmacological inhibition of FTO offers a compelling approach to restoring normal RNA methylation profiles.

FTO inhibitors have shown promising clinical potential since their discovery in 2012. Rhein, a natural product, is a significant FTO inhibitor that inhibits FTO's m⁶A demethylation activity by competing with its active site (Gao *et al.*, 2024). Meclofenamic acid (MA) has been identified as a highly selective FTO inhibitor, leading to an increase in RNA's m⁶A modifications. Two potent small-molecule FTO inhibitors (CS1, CS2) were reported in 2019, showcasing robust anti-tumor effects across various cancer types (Feng *et al.*, 2024). However, the clinical potential of small-molecule FTO inhibitors is limited by moderate activity, toxicity, and low specificity for leukemia stem cells (LSCs) (Su *et al.*, 2021). Researchers developed a glutathione (GSH) bioimprinted nanocomposite material,

GNPIPP12MA, loaded with FTO inhibitors, which targets the FTO/m6A pathway, synergistically enhancing anti-leukemia effects by depleting GSH (Cao et al., 2022).

The development of ALKBH5 inhibitors has gone through several important stages, including high-throughput screening and computer-aided drug design (ACS Omega, 2021). Some promising ALKBH5 inhibitors include citrate, IOX1, MV1035, Ena15, Ena21, 2-(2-hydroxyethylsulfanyl) acetic acid (RD3), 4-[(methyl)amino]-3,6-dioxo (RD6), DO-2728a, and RD3 and RD6, which demonstrate notable inhibitory effects on cancer cell lines (Fang *et al.*, 2025). These compounds can effectively suppress ALKBH5 activity in both in vitro and in vivo models, thereby affecting m6A-modified RNA levels. With further optimization and preclinical studies, these compounds are expected to become new cancer therapies.

RNA-Targeting Strategies

RNA-modifying enzymes and post-transcriptional changes are critical for gene control, but treatment requires specific instruments targeting changed RNA transcripts. Two methodologies have emerged: antisense and RNAi-based technologies for silenced RNAs and CRISPR-Cas13-based platforms for programmable RNA editing. These approaches allow reversible, adjustable, and sequence-specific RNA function modification without genome mutation, expanding therapeutic options for genetic, inflammatory, and degenerative illnesses.

Antisense Oligonucleotides (ASOs) and siRNA-Based Targeting of Modified RNA

The bulk of RNA-based medications used in the clinic or currently under development are antisense oligonucleotides (ASOs) or double-stranded RNA molecules called short interfering RNAs (siRNAs). ASOs and siRNAs both bind target mRNAs, or pre-mRNAs, via complementary Watson-Crick base pairing, but differ in composition and mechanisms of action.

Antisense Oligonucleotide (ASOs)

Antisense Oligonucleotide ASOs are synthetic RNA sequences that selectively attach to a gene's RNA, causing numerous diseases. They can change mRNA processing or degrade the target transcript. Synthesized ASOs can bind to pre-mRNA, influencing splicing events, inhibiting protein translation, or recruiting RNase H to the target transcript (Crooke *et al.*, 2018). Recent studies have revealed that ASOs can be designed to bind

m6A-modified RNA regions, limiting the recruitment of reader proteins such as YTHDF1 or impeding downstream translation. For example, ASOs targeting m6A-modified circRNAs have shown efficacy in inhibiting tumor proliferation in lung and liver malignancies (Qin *et al.*, 2022)

Short interfering RNA (siRNA)

Short interfering RNA (siRNA), contrary, is a double-stranded construct that stimulates the RNAi pathway, a natural cellular defensive mechanism against RNA viruses. Approximately twenty siRNA-based treatments have reached clinical trial stages, targeting disease-causing genes and variations in diseases such as malignancies, inflammatory disorders, and neuropathies. siRNAs targeted to knock down genes with aberrant methylation patterns have been validated in models of glioblastoma, Huntington's disease, and cardiomyopathy (Li *et al.*, 2024). Small interfering ribonucleic acid (siRNA)-based therapeutics have been developed for the past 20 years. The first siRNA agent, patisiran, got US Food and Drug Administration (FDA) approval in 2018. To date, the FDA has approved 6 siRNA agents: patisiran, givosiran, lumasiran, inclisiran, nedosiran, and vutisiran (U.S. FDA, 2018; Padda *et al.*, 2024). Clinically, FDA-approved siRNA medications such as Patisiran (Onpattro) have established the therapeutic promise of this class, and novel ASO-based therapeutics are under development for RNA methylation-linked ailments, including neurodegeneration and splicing-related diseases (Padda *et al.*, 2024). However, there are still considerable challenges to efficient RNA-based therapy options, including distribution to specific regions or tissues, off-target effects, and treatment longevity. Despite these challenges, siRNA remains a promising therapeutic strategy for different disorders.

CRISPR–Cas13-Based RNA Editing Tools

The advancement and swift adoption of CRISPR/Cas technology have facilitated diverse genetic engineering by the targeted recruitment of a Cas endonuclease via a sequence-specific single guide RNA (sgRNA) (Barrangou and Doudna, 2016). Catalytically inactive Cas (dCas) proteins facilitate the recruitment of other protein modes to specific genomic loci without causing DNA strand breaks (Pickar-Oliver and Gersbach, 2019). Likewise, RNA-targeting dCas13 can be conjugated with several protein effectors that alter RNA, hence facilitating RNA modification engineering (Figure 5A) (Abudayyeh *et al.*, 2017; Cox *et al.*, 2017). Thus, RNA modifications can be added or eliminated at specific loci

without necessitating alterations to the main DNA sequence. Successful targeted installation and removal of m⁶A utilizing dCas13-METTL3 and dCas13-ALKBH5, respectively, have been documented (Wilson *et al.*, 2020; Xia *et al.*, 2021; Chen *et al.*, 2022). Likewise, dCas13 conjugated with the deaminase domain of adenosine deaminase acting on RNA type 2 (ADAR2) can facilitate targeted A-to-I RNA editing (Cox *et al.*, 2017; Eisenberg *et al.*, 2018). RNA can be targeted with dCas9 when a single-stranded DNA molecule with a protospacer adjacent motif (PAM) is provided, a method utilized to write and erase m⁶A (Rau *et al.*, 2019; Liu *et al.*, 2019; Ying *et al.*, 2020). Alongside CRISPR/Cas-based molecular tools, endogenous RNA modification machinery can be activated by supplying a sequence-specific guide RNA. Two recent studies have shown that the natural pseudouridylation machinery can be utilized to introduce Ψ onto certain RNA transcripts (Figure 5B) (Adachi *et al.*, 2023; Song *et al.*, 2023). Additionally, native ADAR proteins can be utilized for A-to-I editing through the introduction of exogenous circular guide RNA (Katreka *et al.*, 2022). Molecular tools can also be customized to achieve temporal control of RNA modification engineering. For example, Shi *et al.* created a method for inducible m⁶A modification, where the release of photo-caged abscisic acid upon UV light exposure is essential for tethering dCas13 with METTL3 via adaptor proteins (Figure 5C) (Shi *et al.*, 2022). We believe that the toolset for RNA modification engineering will continue to expand as our understanding of different RNA modifications and their modification machinery advances.




Figure 5: Molecular tools for engineering RNA modifications

High-Throughput Screening for Epitranscriptomic Modulators

High-throughput screening (HTS) has been pivotal in identifying first-in-class small-molecule inhibitors targeting RNA-modifying enzymes. HTS platforms involve the rapid screening of hundreds of thousands of chemical compounds against defined enzymatic or cellular assays to identify hits that modulate activity. For instance, the FTO inhibitor Dac85 was identified via HTS and further optimized into QP73, the first PROTAC degrader targeting FTO. This compound induced potent antileukemic activity by degrading FTO protein selectively and restoring tumor-suppressive m⁶A methylation levels (Liu *et al.*, 2024). Similarly, ALKBH5-specific inhibitors have been discovered using fluorescence-based HTS platforms, capable of discriminating between FTO and ALKBH5 activity through their distinct catalytic pockets (Lai *et al.*, 2024).

Other platforms utilize microfluidics, chemoproteomics, and m⁶A-sensitive biosensors to quantify dynamic methylation levels and screen libraries in cell-based contexts. Integration of HTS with RNA-seq and methylation-specific sequencing has enabled functional validation of inhibitors by monitoring transcriptomic and methylomic shifts in treated cells (Yang *et al.*, 2024).

Structure-Based Drug Design Targeting RNA-Modifying Proteins

Structure-based drug design (SBDD) is rapidly evolving to be a fundamental tool for faster and more cost-effective methods of lead drug discovery. SBDD aims to offer a computational replacement to traditional high-throughput screening (HTS) methods of drug discovery (Martin *et al.*, 2024). Structure-based drug design (SBDD) optimizes high-throughput screening by allowing for the logical, structure-guided improvement of lead compounds, leveraging high-resolution three-dimensional target data.

The atomic structures (X-ray/cryo-EM) of RNA-modifying enzymes, specifically the METTL3-METTL14 writer complex, demethylases FTO and ALKBH5, and various YTH reader domains, have had a direct impact on inhibitor design by revealing cofactor/substrate pockets and allosteric sites that facilitate small-molecule binding.

The m⁶A writer METTL3 has been linked to the initiation and maintenance of acute myeloid leukaemia (AML). Structure-guided campaigns resulted in selective METTL3 binders that reduce AML features in vitro and in vivo. Inhibitors, such as STM2475 and UZH1a, have been observed to occupy the SAM-binding site of METTL3 based on X-ray crystal structures (Moroz-Omori *et al.*, 2021; Yankova *et al.*, 2021). STM2475 and UZH1a

exhibit half-maximal inhibitory concentration (IC₅₀) values of 2.2 and 4.6 μ M, respectively, in MOLM-13 cells and prevent proliferation of AML cell lines (Moroz-Omori *et al.*, 2021; Yankova *et al.*, 2021).

In 2019, two potential FTO inhibitors, FB23 and FB23-2, were developed using structure-based rational design. These inhibitors directly bind to FTO, selectively inhibiting its m⁶A demethylase activity. In vitro, simulating FTO deficiency, FB23-2 significantly inhibited human AML cell proliferation and promoted differentiation and apoptosis. In xenograft mouse models, FB23-2 significantly inhibited the progression of human AML cells (Huang *et al.*, 2029). Rhein, a natural product, is a significant FTO inhibitor. Unlike 2-oxoglutarate analogs or metal ion chelators, Rhein inhibits FTO's m⁶A demethylation activity by competing with its active site, significantly inhibiting m⁶A demethylation within cells (Chen *et al.*, 2012).

Through structure-based virtual screening, Chen *et al.* (2023) recently found two robust FTO inhibitors, CS1 and CS2, with IC₅₀ at nanomolar range in AML cells. CS1 and CS2 selectively occupied the FTO catalytic pocket, thus inhibiting FTO demethylase activity by blocking the interaction between m⁶A-modified substrate and FTO catalytic pocket (Su *et al.*, 2020). Through virtual screening, structural optimization and bioassay, Xie *et al.* developed a novel small-molecule FTO inhibitor, 18,097, which selectively bound to FTO active site and significantly inhibited breast cancer cell proliferation and metastasis both in vitro and in vivo.

The crystal structure of human ALKBH5, comprising 395 amino acids, was elucidated in 2013 (Shen *et al.*, 2022). ALKBH5 is primarily expressed in the testes and lungs, followed by the spleen, kidneys, and liver, with minimal expression in the heart and brain (Chen *et al.*, 2023). The first generation of m⁶A reader inhibitors, including ebselen and fragment-derived YTH binders, were developed by fragment-based screening and structure-guided medicinal chemistry. Li *et al.*, (2020) identified 25 small-molecule ligands of the YTH domain of YTHDC1 by in silico methods, i.e., molecular docking and molecular dynamics simulations. Their crystal structures in the complex with YTHDC1 were solved at high resolution (1.2–1.9 Å). Allosteric modulators impede m⁶A recognition by modifying the reader domain conformation.

The current SBDD toolkit for epitranscriptomic targets includes molecular dynamics (MD) to analyze target flexibility and kinetics, AI-assisted docking/virtual

screening, X-ray/cryo-EM validation, and fragment-to-lead approaches that focus on binding efficiency and ADME features. Together, these resources speed up the identification of candidates with attractive preclinical pharmacology, binding kinetics, and selectivity.

Challenges in Drugging the Epitranscriptome

Specificity and Off-Target Effects

This is a great difficulty in RNA modification targeting, because the solution requires great specificity without inflicting undesired molecular damage. These RNA-modifying enzymes, such as METTL3, FTO, and ALKBH5, often have larger substrate profiles in a range of biological situations. Hence, inhibitors that target these enzymes should not affect non-specific changes or inhibition of other proteins with comparable activities (Höfler and Duss, 2023). The same multiplicity of alterations in epitranscriptomic networks means that inadvertent editing or suppression may alter immunological signaling, the cell cycle, or differentiation. To address this, recent studies are employing rational drug design with fragment-based screening and chemical proteomics to identify inhibitors with enhanced target selectivity. Another recent study has developed allosteric inhibitors that block a regulatory domain exclusively found in each enzyme, and hence tailored to be selectively active against related demethylases (Xie *et al.*, 2023).

Delivery and stability of RNA-targeted medicines in cells

Even if very specific inhibitors are produced, getting them into cells is still an issue. Small chemicals, antisense oligonucleotides (ASOs), and CRISPR-Cas13 constructs that target RNA must get past cellular hurdles such as endosomal entrapment, degradation by nucleases, and immunological activation that isn't the target. For instance, many METTL3 and FTO inhibitors function well in the lab but not so effectively in the body because they do not get across the membrane or get removed by the liver very efficiently. Likewise, siRNA or ASO-based treatments that target RNA methylation usually need chemical modifications (like phosphorothioate backbones) or nanoparticle carriers to keep them from breaking down and to transmit them into the body (Liu *et al.*, 2025).

Lipid nanoparticles (LNPs), PEGylated carriers, and customized conjugates like GalNAc for liver-specific delivery are some of the ways that people are working to increase

stability and uptake. But attaining cell-type-specific accuracy is still hard, notably in the brain, pancreas, and blood-forming organs.

Absence of Structural Data for RNA Modification Complexes

Another challenge that makes it hard to find novel medications in this area is that many RNA modification complexes have not been thoroughly described structurally. There are crystal structures for METTL3-METTL14 and some sections of FTO and ALKBH5, but many reader proteins (such as YTHDF3) and cofactors still don't have their structures figured out. Dynamic RNA-protein interactions, exemplified by the development of liquid-liquid phase-separated granules (LLPS), evade capture by standard X-ray crystallography or cryo-electron microscopy. This makes it harder to create medications that target functional RNA-protein interactions in the body (Guo *et al.*, 2021).

Conclusion

The discipline of epitranscriptomics has developed from a specialist domain into a major pillar of modern biomedical science. RNA modifications such as N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), and pseudouridine (Ψ) have emerged as key regulators of mRNA fate, altering gene expression, cellular plasticity, and disease consequences. Aberrant regulation of RNA-modifying enzymes including writers (e.g., METTL3/METTL14), erasers (e.g., FTO, ALKBH5), and readers (e.g., YTHDFs) has been implicated in the advancement of malignancies, neurological diseases, and immunological dysfunctions. Recent advancements in high-throughput sequencing, direct RNA modification mapping, and single-cell transcriptomics have expanded our capacity to decipher the functional impact of RNA alterations in health and illness. Concurrently, therapeutic breakthroughs ranging from small-molecule inhibitors to RNA-targeting CRISPR-Cas systems are converting epitranscriptomic knowledge into real clinical tactics. The integration of RNA modification signatures into precision medicine, biomarker identification, and drug development pipelines emphasizes the translational momentum of this research. However, to realize the full potential of RNA-targeted therapeutics, obstacles remain: assuring delivery specificity, avoiding off-target effects, standardizing detection technologies, and building adequate regulatory and ethical frameworks. These challenges are surmountable with interdisciplinary collaboration, technological development, and evidence-driven clinical validation.

Recommendations

To promote RNA modification research and its therapeutic application, significant strategic ideas include the establishment of standardized platforms for mapping RNA modifications. This requires upgrading techniques like nanopore direct RNA sequencing and spatial transcriptomics to enhance accuracy and comparability across investigations. Promising medications targeting METTL3, FTO, and ALKBH5 are advancing into clinical trials, backed by mechanisms such as biomarkers and patient stratification using RNA signatures. Incorporating epitranscriptomic profiling into clinical models is critical for predicting responses in disciplines like oncology and neurodegeneration. The use of AI for patient categorization based on transcriptome data is also advocated. Additionally, regulatory frameworks relevant to RNA editing techniques must be devised, addressing ethical problems and ensuring public trust. Cross-sector collaboration and investments in educational programs are necessary for the successful deployment of RNA-based therapeutics

References

- Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., Lander, E. S., Voytas, D. F., Ting, A. Y., & Zhang, F. (2017). RNA targeting with CRISPR-Cas13. *Nature*, 550(7675), 280–284. <https://doi.org/10.1038/nature24049>
- Adachi, H., De Zoysa, M. D., Yu, Y.-T., & Tomita, K. (2023). Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. *Molecular Cell*, 83(4), 637–651.e9. <https://doi.org/10.1016/j.molcel.2023.01.009>
- Artika, I. M., Arianti, R., Demény, M. Á., & Kristóf, E. K. (2025). RNA modifications and their role in gene expression. *Frontiers in Molecular Biosciences*, 12, 1537861. <https://doi.org/10.3389/fmolb.2025.1537861>
- Arzumanian, V. A., Kuleshov, M. V., & Lobanov, A. V. (2022). The role of RNA modifications in health and disease. *International Journal of Molecular Sciences*, 23(5), 2565.
- Bai, X., Liu, Y., & Zhang, Y. (2023). RNA modifications and cancer: Emerging connections and therapeutic implications. *Journal of Cancer Research and Clinical Oncology*, 149(4), 1203–1218.
- Barbieri, I., Kouzarides, T., & Schaefer, M. (2020). Role of RNA modifications in cancer. *Nature Reviews Cancer*, 20(6), 303–322.
- Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. *Nature Biotechnology*, 34, 933–941. <https://doi.org/10.1038/nbt.3659>
- Borchardt, E. K., Martinez, N. M., & Gilbert, W. V. (2020). Regulation and function of RNA pseudouridylation in human cells. *Annual Review of Genetics*, 54, 309–336.

- Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., & Feng, S. (2022). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. *Small*, 18(13), e2106558. <https://doi.org/10.1002/sml.202106558>
- Chang, R., Zhu, S., Peng, J., Lang, Z., Zhou, X., Liao, H., Zou, J., Zeng, P., & Tan, S. (2023). The hippocampal FTO-BDNF-TrkB pathway is required for novel object recognition memory reconsolidation in mice. *Translational Psychiatry*, 13, 1–8.
- Chao, Y., Li, X., & Wang, X. (2021). METTL3 regulates T cell differentiation and proliferation through m6A modification. *Frontiers in Immunology*, 12, 630002.
- Chen, B., Ye, F., Yu, L., Jia, G., Huang, X., Zhang, X., Peng, S., Chen, K., Wang, M., Gong, S., Zhang, R., Yin, J., Li, H., Yang, Y., Liu, H., Zhang, J., Zhang, H., Zhang, A., Luo, C., ... Yang, C.-G. (2012). Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. *Journal of the American Chemical Society*, 134(43), 17963–17971. <https://doi.org/10.1021/ja3064149>
- Chen, L., Li, J., Wang, L., Xu, Y., Zhang, Y., Zhao, Y., Yang, H., & Xu, Y. (2022). METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. *Nucleic Acids Research*, 50(20), 11619–11634.
- Chen, L., Wang, Y., & Zhao, X. (2024). Functional roles of RNA modifications in cancer progression and therapy. *Cancer Letters*, 566, 216256.
- Chen, Y., Wang, W., Zhang, W., He, M., Li, Y., Qu, G., & Tong, J. (2023). Emerging roles of biological m6A proteins in regulating virus infection: A review. *International Journal of Biological Macromolecules*, 253, 126934.
- Chen, Y., Zhou, Z., Chen, Y., & Chen, D. (2024). Reading the m6A-encoded epitranscriptomic information in development and diseases. *Cell & Bioscience*, 14(1), 124.
- Cheng, J., Ma, J., Sun, B., Gao, Y., Zhou, Y., Hu, H., ... Wang, H. (2021). RNA 5-methylcytosine methyltransferases: Functions, regulation, and clinical relevance. *Frontiers in Cell and Developmental Biology*, 9, 640543.
- Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017). RNA editing with CRISPR-Cas13. *Science*, 358(6366), 1019–1027. <https://doi.org/10.1126/science.aag0180>
- Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018). RNA-targeted therapeutics. *Cell Metabolism*, 27(4), 714–739.
- Cui, Q., Shi, H., Ye, P., Li, L., Qu, Q., Sun, G., Sun, G., Lu, Z., Huang, Y., Yang, C.-G., Riggs, A. D., He, C., & Shi, Y. (2017). m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Reports*, 18(11), 2622–2634.
- Du, K., Zhang, Z., Zeng, Z., Tang, J., Lee, T., & Sun, T. (2021). Distinct roles of Fto and Mettl3 in controlling development of the cerebral cortex through transcriptional and translational regulations. *Cell Death & Disease*, 12(7), 700.
- Du, Y., Zhao, Z., & Li, Q. (2024). METTL14 promotes acute myeloid leukemia progression via m6A modification of MYB and MYC. *Leukemia*, 38(2), 456–467.
- Eisenberg, E., & Levanon, E. Y. (2018). A-to-I RNA editing: Immune protector and transcriptome diversifier. *Nature Reviews Genetics*, 19(8), 473–490.
- Esteve-Puig, R., Clot, G., & Guillaumet-Adkins, A. (2020). DNA methylation: Beyond CpG islands. *Nature Reviews Genetics*, 21(8), 492–492.

- Fang, M., Ye, L., Zhu, Y., Huang, L., & Xu, S. (2025). M6A demethylase ALKBH5 in human diseases: From structure to mechanisms. *Biomolecules*, 15(2), 157. <https://doi.org/10.3390/biom15020157>
- Feng, G., Wu, Y., Hu, Y., Shuai, W., Yang, X., Li, Y., Ouyang, L., & Wang, G. (2024). Small molecule inhibitors targeting m6A regulators. *Journal of Hematology & Oncology*, 17(1), 30.
- Fiorentino, F., Menna, M., Rotili, D., Valente, S., & Mai, A. (2023). METTL3 from target validation to the first small-molecule inhibitors: A medicinal chemistry journey. *Journal of Medicinal Chemistry*, 66(3), 1654–1677. <https://doi.org/10.1021/acs.jmedchem.2c01601>
- Gao, Z., Zha, X., Li, M., Xia, X., & Wang, S. (2024). Insights into the m6A demethylases FTO and ALKBH5: Structural, biological function, and inhibitor development. *Cell & Bioscience*, 14(1), 108.
- Gu, X., Wang, L., Zhou, Y., Hu, X., Zhou, J., & Yan, C. (2021). NOP2/NSUN family: Key regulators in RNA methylation and cancer. *Frontiers in Oncology*, 11, 614640.
- Guan, J. (2024). Oncogenic role of METTL3-mediated m6A modification in cancer. *Molecular Cancer*, 23(1), 12.
- Guo, Q., Shi, X., & Wang, X. (2021). RNA and liquid-liquid phase separation. *Noncoding RNA Research*, 6(2), 92–99.
- Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., & He, C. (2023). Anti-tumour immunity controlled through mRNA m5C methylation and YBX1. *Nature*, 615(7953), 564–571.
- Höfler, S., & Duss, O. (2024). Interconnections between m6A RNA modification, RNA structure, and protein-RNA complex assembly. *Life Science Alliance*, 7(1), e202302240. <https://doi.org/10.26508/lsa.202302240>
- Huang, H., Weng, H., & Chen, J. (2020). m6A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. *Cancer Cell*, 37(3), 270–288.
- Huang, W., Qi, C., & Zhang, H. (2019). The emerging role of N1-methyladenosine (m1A) in post-transcriptional regulation. *Cell & Bioscience*, 9(1), 1–11.
- Huang, Y., Su, R., Sheng, Y., Dong, L., Dong, Z., Xu, H., Ni, T., Zhang, Z. S., Zhang, T., Li, C., Han, L., Zhu, Z., Lian, F., Wei, J., Deng, Q., Wang, Y., Wunderlich, M., Gao, Z., Pan, G., ... Yang, C.-G. (2019). Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. *Cancer Cell*, 35(4), 677–691.e10. <https://doi.org/10.1016/j.ccell.2019.03.006>
- Jurkowska, R. Z. (2024). Chromatin regulation by histone-modifying complexes. *Trends in Biochemical Sciences*, 49(1), 1–14.
- Katrekar, D., Yen, J., Xiang, Y., & Mali, P. (2022). Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. *Nature Biotechnology*, 40(6), 938–945. <https://doi.org/10.1038/s41587-021-01171-4>
- Lai, G. Q., Li, Y., Zhu, H., Zhang, T., Gao, J., Zhou, H., & Yang, C.-G. (2024). A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. *RSC Chemical Biology*, 5(4), 335–343.
- Li, M., Cheng, W., Zhang, L., Zhou, C., Peng, X., Yu, S., & Zhang, W. (2022). Novel roles of RNA m6A methylation regulators in the occurrence of Alzheimer's disease and the subtype classification. *International Journal of Molecular Sciences*, 23(18), 10766.

- Li, T., Hu, P., & Chen, X. (2021). Silencing METTL3 attenuates cardiac fibrosis after myocardial infarction. *FASEB Journal*, 35(2), e21257.
- Li, W., Sun, R., & Zhou, X. (2025). METTL3-mediated m6A methylation promotes EMT and metastasis in cancer. *Journal of Experimental & Clinical Cancer Research*, 44(1), 15.
- Li, Y., Bedi, R. K., Nai, F., von Roten, V., Dolbois, A., Zalesák, F., Nachawati, R., Huang, D., & Caflisch, A. (2022). Structure-based design of ligands of the m6A-RNA reader YTHDC1. *European Journal of Medicinal Chemistry Reports*, 5, 100057.
- Liang, Y., Han, H., Liu, L., Duan, T., Zhao, Y., Xu, Q., & Chen, Y. (2024). m6A reader proteins in RNA metabolism, disease, and therapeutics. *Pharmacology & Therapeutics*, 250, 108478.
- Liu, L., Qiu, Y., Suo, Y., Tong, S., Wang, Y., Zhang, X., Chen, L., Huang, Y., Zhou, H., Zhou, H., Dong, Z., & Yang, C.-G. (2024). Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. *Acta Pharmaceutica Sinica B*, 14(12), 5382–5392.
- Liu, M., Wang, Y., Zhang, Y., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025). Landscape of small nucleic acid therapeutics: Moving from the bench to the clinic as next-generation medicines. *Signal Transduction and Targeted Therapy*, 10(1), 73. <https://doi.org/10.1038/s41392-024-02112-8>
- Liu, X. M., Zhou, J., Mao, Y., Ji, Q., Qian, S. B., & Shi, H. (2019). Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates. *Nature Chemical Biology*, 15(9), 865–871. <https://doi.org/10.1038/s41589-019-0327-1>
- Liu, Y., Li, X., Zhou, B., Zhang, X., & Zhao, Y. (2024). The role of pseudouridylation in mRNA translation and stability. *RNA Biology*, 21(1), 1–14.
- Liu, Y., Wang, J., Zhang, Z., Chen, H., & Xu, Y. (2025). N6-methyladenosine modification regulates oxidative stress and inflammation in intervertebral disc degeneration. *Frontiers in Cell and Developmental Biology*, 13, 1547265.
- Liu, Z., Gao, L., Cheng, L., Zhang, Y., Chen, L., & Zhu, W. (2023). The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: Classification, mechanisms, and potential therapeutic implications. *Experimental & Molecular Medicine*, 55, 487–501.
- Lv, J., Zhang, Y., Gao, Y., Xu, S., Zhang, H., & Deng, J. (2021). METTL3-mediated m6A modification regulates Treg cell stability and suppressive function. *Journal of Autoimmunity*, 117, 102576.
- Martin, R. L., Heifetz, A., Bodkin, M. J., & Townsend-Nicholson, A. (2024). High-throughput structure-based drug design (HT-SBDD) using drug docking, fragment molecular orbital calculations, and molecular dynamic techniques. In *Methods in Molecular Biology* (Vol. 2716, pp. 293–306). Springer. https://doi.org/10.1007/978-1-0716-3449-3_13
- Mendel, M., Chen, K. M., Homolka, D., Gos, P., Pandey, R. R., McCarthy, A. A., & Pillai, R. S. (2021). Splice site m6A methylation prevents binding of U2AF35 to inhibit RNA splicing. *Nature*, 598(7882), 332–336.
- Nossent, A. Y., Liu, L., Hansen, T. B., & Kjems, J. (2023). The emerging role of m6A in cardiovascular biology and disease. *Cardiovascular Research*, 119(2), 326–341.
- Ouyang, H., Chen, Z., & Wang, J. (2024). METTL3-mediated m6A methylation enhances metastasis via stabilization of ZEB1 and SNAIL mRNAs. *Cell Death & Disease*, 15, 142.

- Padda, I. S., Kalra, I., & Kalagara, R. (2024). *Small interfering RNA therapeutics*. StatPearls Publishing.
- Paramasivam, A., Priyadharsini, J. V., & Raghunandhakumar, S. (2020). Implications of m6A modification in autoimmune disorders. *Molecular Biology Reports*, 47, 9267–9275.
- Park, C. W., Lee, S. M., & Yoon, K. J. (2020). Epitranscriptomic regulation of transcriptome plasticity in development and diseases of the brain. *BMB Reports*, 53(11), 551–564.
- Pickar-Oliver, A., & Gersbach, C. A. (2019). The next generation of CRISPR-Cas technologies and applications. *Nature Reviews Molecular Cell Biology*, 20, 490–507.
- Qin, Y., Liu, X., Pan, Y., & Liu, J. (2022). The m6A-modified circular RNAs in cancer progression: Roles, mechanisms, and potential applications. *Frontiers in Oncology*, 12, 891276.
- Qui, Y., Xu, Z., Zhang, X., & Zhou, L. (2023). Epitranscriptomic regulation of gene expression: Focus on m6A and m5C. *Cellular and Molecular Life Sciences*, 80(1), 1–21.
- Rau, K., Rentmeister, A., & Reimann, R. (2019). Sequence-specific m6A demethylation in RNA by FTO fused to RCas9. *RNA*, 25(10), 1311–1323.
- Shen, D., Wang, B., Gao, Y., Zhao, L., Bi, Y., Zhang, J., Wang, N., Kang, H., Pang, J., Liu, Y., Pang, L., Chen, Z.-S., Zheng, Y.-C., & Liu, H.-M. (2022). Detailed resume of RNA m6A demethylases. *Acta Pharmaceutica Sinica B*, 12(5), 2193–2205. <https://doi.org/10.1016/j.apsb.2022.01.003>
- Shi, H., Wei, J., & He, C. (2020). Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. *Molecular Cell*, 78(1), 1–16.
- Song, H., Zhang, J., Liu, B., Xu, J., Cai, B., Yang, H., Straube, J., Yu, X., & Ma, T. (2022). Biological roles of RNA m5C modification and its implications in cancer immunotherapy. *Biomarker Research*, 10(1), 15.
- Song, J., Zong, J., Yu, Y.-T., & Li, X. (2023). CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. *Molecular Cell*, 83(1), 139–155.e9. <https://doi.org/10.1016/j.molcel.2022.11.011>
- Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., Li, C., Zhao, Z., Robinson, S., Tan, B., Qing, Y., Qin, X., Prince, E., Xie, J., Qin, H., Li, W., ... Chen, J. (2020). Targeting FTO suppresses cancer stem cell maintenance and immune evasion. *Cancer Cell*, 38(1), 79–96.e11.
- Sun, T., Wu, R., & Ming, L. (2023). The role of m6A RNA methylation in cancer metabolism. *Molecular Cancer*, 22(1), 1–16.
- Sweef, M., Alshahrani, M., & Wang, W. (2024). N1-methyladenosine (m1A) modification in human diseases. *Frontiers in Molecular Biosciences*, 11, 1304567.
- Thalhammer, A., Bencokova, Z., Poole, R., Loenarz, C., Adam, J., O'Flaherty, L., & Pollard, P. J. (2011). Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor-1 α (HIF-1 α). *PLoS ONE*, 6(1), e16210.
- Tooley, J. G., Catlin, J. P., & Schaner Tooley, C. E. (2023). METTLing in stem cell and cancer biology. *Stem Cell Reviews and Reports*, 19(1), 76–91. <https://doi.org/10.1007/s12015-022-10444-7>

- U.S. Food and Drug Administration. (2018, August 14). *New class of drugs fulfills promise of RNA-based medicine*. <https://www.fda.gov/drugs/spotlight-cder-science/new-class-drugs-fulfills-promise-rna-based-medicine>
- Wang, J., Yan, S., Lu, H., Wang, S., Xu, D., & Xu, Z. (2021). Role of m6A RNA methylation in immunoregulation and autoimmunity. *Frontiers in Cell and Developmental Biology*, 9, 757677.
- Wang, X., Li, Z., & Zhang, Y. (2024). m1A RNA modification: Mechanisms, functions, and disease relevance. *RNA Biology*, 21(2), 200–214.
- Wang, X., Ma, X., Chen, S., Fan, M., Jin, C., Chen, Y., Wang, S., Wang, Z., Meng, F., Zhang, C., & Yang, L. (2024). Harnessing m1A modification: A new frontier in cancer immunotherapy. *Frontiers in Immunology*, 15, 1517604. <https://doi.org/10.3389/fimmu.2024.1517604>
- Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., & He, C. (2015). N6-methyladenosine modulates messenger RNA translation efficiency. *Cell*, 161(6), 1388–1399.
- Wen, J., Lv, R., Ma, H., Shen, H., He, C., Wang, J., & Shi, Y. (2024). YTHDF1 regulates dendritic cell-mediated immune response via m6A-dependent translation of immune transcripts. *Nature Communications*, 15, 1124.
- Wilkinson, A., Ji, D., Papa, F., & Schaefer, M. (2022). The dynamic life of m6A RNA modification. *Nature Reviews Genetics*, 23(8), 499–512.
- Wilkinson, J., Thalhammer, A., Loenarz, C., & Schofield, C. J. (2021). Regulation of the ALKBH5 RNA demethylase in hypoxia. *Biochemical Journal*, 478(7), 1483–1501.
- Wilson, C., Chen, P. J., Miao, Z., & Liu, D. R. (2020). Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. *Nature Biotechnology*, 38(12), 1431–1440. <https://doi.org/10.1038/s41587-020-0572-6>
- Wong, J. M., & Eirin-Lopez, J. M. (2021). Evolution of methyltransferase-like (METTL) proteins in Metazoa: A complex gene family involved in epitranscriptomic regulation and other epigenetic processes. *Molecular Biology and Evolution*, 38(12), 5309–5327.
- Xia, Z., Tang, H., Wang, S., He, S., Zhang, L., & Chen, S. (2021). Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. *Nucleic Acids Research*, 49(13), 7361–7374. <https://doi.org/10.1093/nar/gkab517>
- Xie, G., Wu, X.-N., Ling, Y., Rui, Y., Wu, D., Zhou, J., et al. (2022). A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. *Acta Pharmaceutica Sinica B*, 12(2), 853–866. <https://doi.org/10.1016/j.apsb.2021.08.028>
- Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023). Recent advances in targeting the “undruggable” proteins: From drug discovery to clinical trials. *Signal Transduction and Targeted Therapy*, 8(1), 335. <https://doi.org/10.1038/s41392-023-01589-z>
- Xiong, X., Li, X., & Yi, C. (2022). N1-methyladenosine methylome in eukaryotic messenger RNA and its biological implications. *Nature Structural & Molecular Biology*, 29(4), 271–280.
- Xu, Y., Zhang, Y., & Zhang, J. (2022). Epigenetic regulation by histone modifications in cancer. *Nature Reviews Cancer*, 22(11), 671–686.

- Xue, C., Zhao, Y., & Li, L. (2022). RNA methylation in plant and human biology. *RNA Biology*, 19(5), 569–583.
- Yang, Y., Hsu, P. J., Chen, Y. S., & Yang, Y. G. (2022). Dynamic transcriptomic m6A decoration: Writers, erasers, readers and functions in RNA metabolism. *Cell Research*, 32(5), 499–516.
- Yang, Y., Lu, Y., Wang, Y., Wen, X., Qi, C., Piao, W., & Jin, H. (2024). Current progress in strategies to profile transcriptomic m6A modifications. *Frontiers in Cell and Developmental Biology*, 12, 1392159.
- Yao, Y., Yang, Y., Guo, W., Xu, L., You, M., Zhang, Y., & Han, J. (2021). METTL3-dependent m6A modification programs dendritic cell activation. *Nature Communications*, 12, 5826.
- Ying, X., Jiang, X., Zhang, H., Liu, B., Huang, Y., & Zhang, H. (2020). Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase-like 3 conjugates promotes bladder cancer development. *Molecular Cancer*, 19(1), 1–6.
- Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., & Semenza, G. L. (2016). Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. *Proceedings of the National Academy of Sciences of the United States of America*, 113(14), E2047–E2056. <https://doi.org/10.1073/pnas.1602883113>
- Zhang, J., Tong, L., Liu, Y., Li, X., Wang, J., Lin, R., Zhou, Z., Chen, Y., Chen, Y., Liu, Y., & Chen, D. (2023). The regulatory role of m6A modification in the maintenance and differentiation of embryonic stem cells. *Genes & Diseases*, 11(5), 101199.
- Zhang, X., Li, H., & Chen, Y. (2021). m5C modification in RNA: Mechanisms and implications in human disease. *Frontiers in Genetics*, 12, 730682.
- Zhang, X., Li, J., Zhou, X., Liu, Y., Wang, Z., & Li, L. (2024). METTL3 in immune regulation and autoimmune disease pathogenesis. *Autoimmunity Reviews*, 23, 103453.
- Zhao, B. S., Wang, X., Beadell, A. V., Lu, Z., Shi, H., Kuuspalu, A., Ho, R. K., & He, C. (2017). m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. *Nature*, 542(7642), 475–478. <https://doi.org/10.1038/nature21355>
- Zhao, F., Xu, Y., Gao, S., Qin, L., Austria, Q., Siedlak, S. L., Pajdzik, K., Dai, Q., He, C., Wang, W., O'Donnell, J. M., Tang, B., & Zhu, X. (2021). METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events. *Molecular Neurodegeneration*, 16(1), 70. <https://doi.org/10.1186/s13024-021-00484-x>
- Zhao, Y., Dunker, W., Yu, Y.-T., & Karijovich, J. (2018). The role of noncoding RNA pseudouridylation in nuclear gene expression events. *Frontiers in Bioengineering and Biotechnology*, 6, 8. <https://doi.org/10.3389/fbioe.2018.00008>
- Zhao, Y., Wang, X., & Li, X. (2025). Pseudouridine and its functional implications in RNA biology. *Trends in Biochemical Sciences*, 50(1), 12–25.
- Zou, J., Guo, Y., Zhao, Y., Pan, W., Xu, J., & Su, S. (2024). N6-methyladenosine modification of SARS-CoV-2 RNA facilitates immune evasion and viral replication. *Cell Reports*, 42, 113452.